McGuire 1989.

Methods	Randomised Phase III trial 1984 to 1987
Participants	394 patients with histologically confirmed squamous carcinoma of the cervix, recurrent disease following primary therapy or metastases. No previous chemotherapy allowed
Interventions	Arm 1: carboplatin 400 mg/m2 d1 q28 Arm 2: iproplatin 270 mg/m2 d1 q28
Outcomes	Response rates Response duration Toxicity (GOG) OS
Notes	23 ineligible (7 non‐squamous histology, 4 other primaries, 8 previous other malignancy, 3 no pathological documentation of primary tumour, 1 previous chemotherapy). 10 additional patients not evaluable for toxicity or response. 7 did not receive treatment. 3 lost to follow‐up. ITT analysis not performed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block design with balanced assignments
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	23 ineligible and 10 additional patients not evaluable for toxicity or response balanced across groups. ITT analysis not performed
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	Low risk	No hint at any other possible biases